Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Comment by JayjayUSA12007on Aug 26, 2019 11:30pm
119 Views
Post# 30068446

RE:RE:RE:Unreal

RE:RE:RE:Unreal
Quote:"The key thing for the stock is to get that additional visibility and that seems to only come via a share issue. Companies inthe NASH space that have offered shares recently (AKRO, NGM, GNFT) have market caps of $660 million to $1.2 billion. On the other hand, GALT, another NASH player who recently did a company-backed rights issue versusu selling shares through Wall Street brokers, has a  market cap of $187 million despite being further along inthe testing process than any of the three companies that issued shares through brokers."

Have you changed your mind, SPCEO1 ?
You seem to be OK with a low-ball secondary ! I recall you firmly believed it not going to happen.
What you think the offering price gonna be ? No one would offer a price more than its market price which is currently at $C 5.xx and $USD 4.xx . Are you OK with an secondary offering lower than this market price ?
Bullboard Posts